SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO )
CNTO 0.000010000.0%Feb 6 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: .com who wrote (26)10/28/1996 10:35:00 AM
From: Thean   of 965
 
MALVERN, Pa., Oct. 28 /PRNewswire/ -- Centocor Inc announced today that the EPILOG trial demonstrated that
ReoPro(TM) achieved a statistically significant improvement versus placebo at six months in the primary composite endpoint of
death, MI, and revascularization. Statistically significant differences in target revascularization were maintained in non-diabetics.
Statistical significance in death, MI, and urgent intervention was achieved in major subgroups including diabetics over six
months.

"The achievement of the six month endpoint further underscores the clinical value of ReoPro," said David P. Holveck, President
and Chief Executive Officer.

Further details of the six month data from the EPILOG trial will be disclosed at the American Heart Association conference in
New Orleans.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News